Master Alliance Provisions Guide (MAPGuide)

NIH – MPP, COVID-19 Patent and Biological Material License Agreement

  • Business model | Product supply
  • Equitable Access | Territory access commitments

10. Performance


10.3 The Licensee agrees to require each of its Sublicensee(s), after that Sublicensee’s First Commercial Sale, to make reasonable quantities of Licensed Products or materials produced through the use of Licensed Processes available to patient assistance programs.